Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Grande Portage Resources (V.GPG) Initiates Sensor-Based Ore Sorting Testwork (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Passage Bio Inc PASG

Healthcare Biotechnology
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional... see more

Recent & Breaking News (NDAQ:PASG)

Passage Bio Announces Gene Therapy Manufacturing Research and Development Site

GlobeNewswire December 16, 2020

Passage Bio Receives MHRA Clinical Trial Authorization for PBGM01 for Treatment of GM1 Gangliosidosis

GlobeNewswire December 10, 2020

Passage Bio Teams with Catalent to Start CGMP Manufacturing for Lead Gene Therapy Products

GlobeNewswire December 7, 2020

Passage Bio to Present at Piper Sandler 32nd Annual Healthcare Conference

GlobeNewswire November 23, 2020

Passage Bio Highlights University of Pennsylvania's Gene Therapy Program's Newly Published Research to Prevent Toxicity Associated with Gene Therapy

GlobeNewswire November 11, 2020

Passage Bio to Participate in Upcoming November Investor Conferences

GlobeNewswire November 11, 2020

Passage Bio Reports Third Quarter 2020 Financial Results and Recent Business Highlights

GlobeNewswire November 10, 2020

Passage Bio and Invitae Announce Collaboration to Facilitate Genetic Testing to Support Early Diagnosis and Greater Awareness of Clinical Trials for Patients with GM1

GlobeNewswire November 9, 2020

Passage Bio to Report Third Quarter 2020 Financial Results on November 10, 2020

GlobeNewswire November 4, 2020

Passage Bio's PBKR03 Receives Orphan Drug and Rare Pediatric Disease Designations from FDA for Treatment of Krabbe Disease

GlobeNewswire October 28, 2020

Passage Bio's PBGM01 Receives Orphan Drug Designation from EMA for Treatment of GM1 Gangliosidosis

GlobeNewswire October 26, 2020

Passage Bio Announces Publication of Preclinical Data That Show Single Injection of Optimized AAV Vector into Cerebral Spinal Fluid Corrects Neurological Disease, Supporting Advancement of PBGM01 into Clinic

GlobeNewswire October 13, 2020

Passage Bio to Participate in 2020 Virtual Cell & Gene Meeting on the Mesa

GlobeNewswire October 6, 2020

Passage Bio to Participate in Upcoming October Investor Conferences

GlobeNewswire September 25, 2020

Passage Bio Announces Publication of Preclinical Gene Therapy Study Data from Frontotemporal Dementia Program

GlobeNewswire September 17, 2020

Passage Bio to Participate in Citi's 15th Annual BioPharma Virtual Conference

GlobeNewswire September 3, 2020

Passage Bio Reports Second Quarter 2020 Financial Results and Recent Business Highlights

GlobeNewswire August 13, 2020

Passage Bio to Report Second Quarter 2020 Financial Results on August 13, 2020

GlobeNewswire August 7, 2020

Passage Bio Added to Russell 2000 Index

GlobeNewswire June 26, 2020

Passage Bio to Present at Goldman Sachs 41st Annual Global Healthcare Conference

GlobeNewswire June 4, 2020